Oxaliplatin is a third-generation platinum-based chemotherapeutic drug used primarily in the treatment of colorectal cancer. Its unique mechanism of action, combining with DNA to inhibit replication, makes it an essential component in oncology. The importance of oxaliplatin in cancer treatment underscores the need for reliable and quality manufacturers who ensure its accessibility to patients worldwide. This comprehensive overview explores the leading manufacturers of oxaliplatin, their manufacturing processes, and their commitment to quality and accessibility. Manufacturers of oxaliplatin

must comply with stringent regulatory requirements set by health authorities such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other national regulatory bodies. Compliance with these regulations ensures that the drug is safe, effective, and of high quality.